QBiotics Group Limited

Naturally Inspired. Scientifically Defined

Trade Now

Naturally Inspired. Scientifically Defined








Investment Highlights

  • Discovers, Develops, and Commercialises novel anticancer and wound healing pharmaceuticals

  • Proven ability to partner successfully and commercialise products with global global industry leaders

  • Diverse and experienced team with over 20 years track record

Company Overview

  • Simultaneous human and veterinary development model

    Delivers earlier returns and reduces risks for human development

  • Treating tumours & wounds with high-value, inter-related programmes

    Human oncology & would healing pharmaceutical

  • Proprietary drug discovery platform EcoLogic™

    Offer potential for long term growth targeting only the best biologically active molecules

  • Veterninary pharmaceuticals already in the market

    Marketing veterinary drug STELFONTA in the US, Europe and Australia

QBiotics research and development program is based on compounds derived from the Australian tropical rainforest.

The product focus addresses unmet medical needs for humans and companion animals, with a concentration on the global health priority areas of cancer, specifically solid tumours, and chronic wound management.

QBiotics is an Australian life sciences company, inspired by nature to improve human and animal health.

Pursuing both monotherapy and combination therapy avenues in clinical trials to test efficacy and safety – results of these studies provided a clinically relevant and highly validated model for cancer in humans

Current Market Cap >A$500M

850,000 shares available



Additional Information

  • Financials


  • Management
  • Directors
  • Dr Peter Schmidt

    Chief Operating Officer

  • Michael Wenzel

    Chief Financial Officer

  • Mary Phipps

    Chief Marketing Officer

  • Dr Richard Yocum

    Chief Medical Officer

  • Roberta Bozzili

    Chief Legal & Commercial Officer

  • Ebru Davidson

    General Counsel

  • Dr Tracey Mynott

    Business Development Manager

  • Dr Sam Yurdakul

    Director of Prduct Development

  • Rick Holliday-Smith AM

    Non-Executive Chairman

  • Dr Victoria Gordon

    Managing Director & CEO

  • Dr Paul Reddell

    Executive Director & Chief Scientific Officer

  • Nicholas Moore

    Non-Executive Director

  • Dr Susan Foden

    Non-Executive Director

  • Andrew Denver

    Non-Executive Director

  • Professor Bruce Robinson AC

    Non-Executive Director

  • Associate Professor Steven Ogbourne

    Non-Executive Director

  • Neville Mitchell

    Non-Executive Director

  • Hamish Corlett

    Non-Executive Director


  • March 2022

    Development to speed drugs to market
    Read more
  • June 2021

    Qbiotics concludes successful A$85M capital raise
    Read more

Ask us a question

Ask Us a Question

Already a member?

Login now

Become a member

Register now

    Thank you for your enquiry.
    We will be in touch as soon as possible.